Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.
Gerard SocièNoel MilpiedIbrahim Yakoub-AghaJacques-Olivier BaySabine FürstKarin BilgerFelipe SuarezMauricette MichalletPhilippe LewalleDavid LiensCatherine MathisEric GuemasJean-Paul VernantPublished in: Blood advances (2020)